Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)

NCT01190254 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia, Paranoid
Schizophrenia, Disorganized
Schizophrenia, Undifferentiated

Interventions

DRUG: asenapine 2.5 mg
DRUG: asenapine 5.0 mg
DRUG: placebo

Sponsor

Organon and Co